Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a single-center clinical research study with the purpose to evaluate the safety,
tolerability, and pharmacokinetics (PK) of nalbuphine HCl ER (extended release) tablets in
end-stage renal disease (ESRD) patients receiving hemodialysis (HD) therapy and reporting
pruritus.